Background and Aims: Long-term lamivudine therapy is required for patients with chronic hepatitis B, because hepatitis reappears frequently after it has withdrawn. However, hepatitis B virus (HBV) ...

Entecavir is indicated for the treatment of CHB in adults with compensated liver disease and evidence of active viral replication and either elevated ALT/aspartate aminotransferase (AST) levels or ...

The Appraisal Committee considered evidence submitted by the manufacturer of entecavir and a review of this submission by the Evidence Review Group (ERG). The manufacturer approached the initial ...

Chronic hepatitis B (CHB) poses a major global health burden, with China particularly affected. Effective antiviral therapy ...

Please provide your email address to receive an email when new articles are posted on . There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking ...

Long-term mortality outcomes were similar in patients with CHB receiving treatment with entecavir or tenofovir. Patients with chronic hepatitis B (CHB) treated with entecavir vs tenofovir disoproxil ...

Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B. Histologic ...

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Entecavir Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. A thorough market analysis on ...